Thermo Fisher Scientific Inc. (NYSE:TMO) closed its $260 million deal to acquire Fermentas International Inc.
Burlington, Ont.-based Fermentas, which runs its principal operation out of Vilnius, Lithuania, makes enzymes, reagents and molecular weight markers. The company, which employs about 500 workers, posted sales of about $55 million last year.
Thermo Fisher said it integrate Fermentas into its analytical technologies division.
When it announced the deal in May, Thermo Fisher said the deal will expand its polymerase chain reaction portfolio for its molecular and cell biologist customers. The Waltham, Mass.-based lab instruments giant plans to integrate Fermentas into its analytical technologies segment once the deal is consummated, likely during the third quarter.
The announcement capped a string of deals for TMO, which beefed up its PCR offering with Finnish polymerase chain reaction equipment maker Finnzyme in February and added to its proteomic portfolio with Odense, Denmark-based Proxeon in April.
But it’s the one that got away that looms largest. In February Thermo Fisher reportedly lost out in a bidding war over Millipore Corp. (NYSE:MIL). Merck KGaA (NYSE:MRK), a German chemical and pharmaceuticals manufacturer, won that tussle with a $7.2 billion, $107-a-share offer, including acquired debt. Merck closed that deal last week, saying that several Millipore executives would stay with its new EMD Millipore division but that former CEO Martin Madaus would depart after assisting with the transition.